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Abstract This study examined eYcacy of the innate
immune defence via the mannose binding lectin (MBL) in a
cohort of 55 dystonic patients prospectively referred to the
clinic with laryngeal mucosal complaints, who were placed
on local steroids (budesonid inhaler, 400 g 2 times daily)
and antihistamines (fexofenadin 180 mg mostly 3 times
daily) with adjuvant lifestyle corrections. Treatment eYcacy
of the larynx was assessed based on mucosal Wndings of the
vocal folds examined with phonatory function studies
(PhFS) comprising simultaneous high-speed digital images,
kymography, electroglottography and voice acoustics com-
bined with a visual score of arytenoids oedema, as these
measures are indicative of the magnitude of laryngitis. Lac-
tose and gluten intolerance and immunological analyses of
the innate system were made systematically. Results
showed that the genetic aspects of immunology did not
reveal a role for the innate immune system, represented by
the MBL. But an unexpected positive eVect of the larynx
treatment on dystonia symptoms was found evidenced by
reduction of dystonic complaints and more normative
results of PhFS, and a reduction of oedema of the inter ary-
tenoids region. Symptoms relieve and better quality of life
was observed on follow-up for the dystonia complaints.
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Introduction
Dystonia represents a neurological syndrome dominated by
involuntary muscle contractions, with several kinds of dys-
tonia recognised clinically. Theories of the development of
dystonia include genetic- and immunological aspects and
also acute provocations by, e.g. infection disorders. Spe-
ciWc stress provocations are seldom referred to in the litera-
ture. Syndromes of dystonia are clinically and genetically
heterogenic disorders, the recent aspects include that the
disorder can be reversible [1, 2].
Treatment options of dystonia are historically rarely
documented in prospective randomised controlled studies,
although a more constant symptom eVect is obtained with
the painful injections of neurotoxins with one product in
an evidence-based study comparing two diVerent products
[3–7].
Treatments are often related to lifestyle [8]. Since 1976
treatment of laryngeal spasmodic dystonia is controlled by
unilateral section of the recurrent nerve denervation either
surgically or chemically. Through this approach under-
standing of laryngeal dystonia has been gained, and system-
atic diagnosis and treatment of spastic dysphonia was
presented by Dedo and Izdebski [9, 10], yet, randomised
controlled trials of treatment of spasmodic dystonia have
not been made [11].
Materials and methods
The 55 dystonia patients with an average age of 55 years
were included prospectively in this observational cohort
study [12] for 8 months The patients included 14 males
(25.5%) and 41 females (74.5%) who had experienced
dystonia-related symptoms of chronic laryngitis (mucosal
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symptoms) for an average of 13 years. The symptom dura-
tion time was between half a year and 42 years (Table 1).
The localisation of the dystonia symptoms with laryngeal
mucosal symptoms is presented in Table 2. Only 2 patients
had genetic lactose intolerance and 1 had gluten intolerance
out of the 55 dystonia patients. Out of nine patients exam-
ined for various dystonia genes 2 (22%) had DYT 1 genes.
Botox had been given to all patients in the Danish hospital
system. From the systematic blood test, 26 (47%) patients
had a reduced function of the innate immune system (MBL
<500 g/L).
Because the population described here presented symp-
toms of “laryngitis”, they were subjected to its treatment.
Laryngitis complaints included: sore throat, dysphonia and
mucosal complications. The intention was to evaluate an
eventual immunological factor with the use of phonatory
function studies (PhFS).
To assure objectivity of treatment eYcacy, speciWc
objective techniques (PhFS) capable of describing changes
within vocal folds were employed. These included, high-
speed digital imaging of the vocal folds, kymography, EGG
and acoustics [13–18].
At the Wrst examination, the duration and speciWc symp-
toms of laryngitis and the dystonia syndrome were dis-
cussed with the patients. Findings were stored in the data
Wle and included visual scores of vocal folds regularity and
abnormal inter arytenoids oedema on high speed digital
images (HSDI), as earlier described [18], 1 being normal
and 5 being maximal oedema closing the glottis. A plan for
life style correction, local steroid inhaler of budesonid in
the upper airways and the antihistamine fexofenadin was
made. Medication of local steroids (budesonid inhaler,
400 g 2 times daily) and antihistamines (fexofenadin
180 mg mostly 3 times daily) as well as lifestyle correction
was given, based on mucosal Wndings. Lifestyle correction
advice was related to upper airway infections, allergies and
laryngo-pharyngeal reXux.
Physiologic adductor mobility of the vocal folds
obtained from high-speed recordings were measured at
three locations, corresponding to classical demarcation
lines used in vocal folds segmentation: front, centre and
rear part of the vocal cords during intonation, and the
acoustical measures based on the high-speed Wlms were
performed. This is illustrated in Fig. 4. Measurements
included quantitative measurement of the area between the
vocal folds in the front, middle and rear parts. Qualitative
evaluation of the regularity of vocal folds mobility and
motility were assessed using kymography, electroglottogra-
phy (EGG) and acoustics obtained simultaneously.
The multivariate voice analyses (Laryngograph Ltd.)
were made combined with the high-speed images, fre-
quency and intensity measures of a sustained tone/ah/as
well as reading of a standard phonetically balanced text
(“The Northern Wind and the Sun”). Electroglottography of
the closed phases of the vocal cords vibratory cycle was
calculated in a standard manner.
All measurements were repeated 2–3 weeks later. Fol-
low-up was conducted 6–12 months later with a question-
naire sent to the patients to establish if the improvement
was sustained.
Results
In general, all 55 dystonic cases in the prospective cohort
study of the dystonic patients showed elimination or signiW-
cant clinical reduction of symptoms for “laryngitis”. Most
surprisingly, we observed over the course of treating these
55 cases that all consecutive cases showed various
responses with regard to their underlying aetiology, namely
that dystonia severity was aVected as a function of this
treatment of the upper respiratory component, the larynx,
including the vocal folds.
Our  Wrst dystonia patient (Fig. 1) where high-speed
images were used to document changes showed total
Table 1 Patient description
Females 
(N = 41)
Males 
(N =1 4 )
Total 
(all patients) 
(N =5 5 )
Age (years)
Mean 57.0 50.7 55.4
SD 12.9 16.1 13.9
Range 29–79 9–69 9–79
Symptom duration (years)
Mean 11.7 15.9 12.7
SD 11.2 14.4 12.1
Range 0.5–50 3–41 0.5–50
MBL
<500 g/L 19 (46%) 7 (50%) 26 (47%)
>500 g/L 17 (42%) 4 (29%) 21 (38%)
Missing 5 (12%) 3 (21%) 8 (15%)
Table 2 Number of patients in each subdivision of dystonia symp-
toms
Symptoms 1st consultation 2nd consultation 
after 2–3 weeks
n (%) Average 
improvement (%)
Range (%)
Laryngeal 55 (100)
Focal symptoms 36 (65) 40 0, 1–75
Segmental 18 (33) 20 0–50
Multifocal 21 (38) 31 0–50
General 26 (47) 60 0–98Eur Arch Otorhinolaryngol (2012) 269:1477–1482 1479
123
elimination of universal dystonia symptoms. In addition, PhFS
showed regularity of laryngeal actions. The elimination of
dystonia in the larynx and in other parts of the body in some
of these patients suggested a relationship between immuno-
logical deWciencies of the upper airways and the nature of
dystonia, with relapses when the medication was termi-
nated (Tables 1, 2).
What can account for this? Fexofenadin works as an anti
inXammatory agent inXuencing the brain. Local steroids
(budesonid) also work in an anti inXammatory way. A
focus was also placed on the innate immune system, man-
nose binding lectin (MBL) since this is a very active agent
in the early defence of the mucosa [19–23].
The overall high-speed images measures of the open
quotients between the vocal cords are presented at the Wrst
and second examination in Table 3, second examination
conducted 2–3 weeks later. The change in closure was sig-
niWcant in front and the middle part of the vocal cords from
the measures for patients over time.
The oedema of the arytenoids regions was statistically
signiWcantly reduced (p = 0.0003), but with no diVerence
between normal versus abnormal MBL values as seen in
Table 4.
Fig. 1 The Wrst patient before and after treatment
Table 3 High-speed Wlms and MDVP results statistical analysis
* Statistically signiWcant on a 5% signiWcance level
a Test in the linear statistical model where MBL is included as a Wxed eVect and baseline is included as a covariate
1st consultation 2nd consultation after 2–3 weeks Change (2nd¡1st consultation)
N Mean Std N Mean Std N Mean Std p value
Open quotient front
All dystonia patients 53 0.51 0.29 44 0.60 0.28 44 0.11 0.36 0.014*
MBL <500 g/L 25 0.53 0.30 20 0.60 0.27 20 0.08 0.32
MBL >500 g/L 21 0.54 0.27 17 0.57 0.34 17 0.05 0.40
MBL <500 g/L versus MBL >500 g/L 0.80a
Open quotient middle
All dystonia patients 53 0.51 0.26 44 0.60 0.26 44 0.09 0.34 0.023*
MBL <500 g/L 25 0.50 0.24 20 0.60 0.24 20 0.09 0.34
MBL >500 g/L 21 0.56 0.27 17 0.61 0.31 17 0.06 0.34
MBL <500 g/L versus MBL >500 g/L 0.99a
Open quotient rear
All dystonia patients 53 0.59 0.26 44 0.59 0.30 44 ¡0.02 0.37 0.65
MBL <500 g/L 25 0.58 0.22 20 0.63 0.28 20 0.02 0.32
MBL >500 g/L 21 0.66 0.28 17 0.59 0.32 17 ¡0.10 0.40
MBL <500 g/L versus MBL >500 g/L 0.58a
MDVP (reading)
Reading variation 0.17
Frequency% 32 17.65 17.31 15 11.14 6.18 12 ¡2.45 10.54
Reading intensity% 32 15.73 6.02 15 18.54 7.34 12 3.67 7.36 0.13
Reading Qx% 32 46.19 7.42 15 46.97 6.24 12 ¡0.55 5.79 0.73
MDVP (sustained tone)
Tone Jitter% 31 6.97 14.49 15 4.07 5.30 11 0.70 5.46 0.68
Tone Shimmer% 31 13.20 13.57 15 9.70 9.24 11 ¡0.77 7.46 0.75
Tone Qx% 31 47.85 11.04 15 49.93 10.61 11 3.24 5.86 0.111480 Eur Arch Otorhinolaryngol (2012) 269:1477–1482
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The assessment of the severity of disease at the follow-
up showed an improvement of 18.3 (p = 0.0001) and an
improvement for the quality of life of 7.3 (p = 0.073) as
seen in Figs. 2 and 3.
In Table 3, the acoustical measures before and after rou-
tine treatments of the patient’s complaint of symptoms of
the larynx are presented. Notably, the electroglottographi-
cal measures showed no signiWcance of change related to
the upper airway mucosa, corresponding to the kymogra-
phy measures in the HSDI. Other new measures of voice
quality might show quantitative diVerences related to high-
speed Wlms of dystonia. Still no evidence exists till now.
The subdivisions of diagnoses of the dystonia cases were
seen in Table 2. Mostly the shorter the duration of symp-
toms, the better eVect of treatment of the upper airways was
seen. The oedema was reduced of the arytenoids region in
the back of the larynx with treatment of the upper airways.
No diVerence was seen for the innate immune system com-
ponent (MBL). The open quotients during intonation on
high-speed  Wlms showed no diVerence between patients
with abnormal MBL <500 g/L and normal MBL >500 g/L.
The basic function of MBL in the innate immune system
was illustrated in the book by Parham [22]. It attacks all
pathogens coming into the body in a systematic way, very
diVerent from the adaptive defence system which does not
seem to be involved here.
Discussion
Randomised controlled studies are necessary in the future
for various aspect of treatment of dystonia [12]. It was
found in the presented prospective observational cohort
study that the immune system in the dystonic population
treated for symptoms of laryngitis complaints was opti-
mised locally in the larynx, but also that some dystonia
symptoms were reduced. This was a stunningly surprising
outcome.
So, how can we account for this localised treatments
eVect on dystonic symptoms in this population? Although
we tried to Wnd detailed physiological and pharmacological
documentation of the traditional medications used for dys-
tonia, none had the suYcient evidence normally required in
the Cochrane library, positively and negatively. In our
study, the MBL part of the immune system did not seem to
Table 4 High-speed Wlms inter-arytenoid region oedema statistical analysis
*** Statistically signiWcant on a 0.1% signiWcance level
a Test in the linear statistical model where MBL is included as a Wxed eVect and baseline is included as a covariate
1st consultation 2nd consultation Change (2nd–1st consultation)
N Mean Std N Mean Std N Mean Std p value
All dystonia patients 55 2.71 0.60 49 2.35 0.63 49 ¡0.35 0.72 0.0003***
MBL <500 g/L 26 2.69 0.62 22 2.32 0.57 22 ¡0.36 0.73
MBL >500 g/L 21 2.67 0.58 20 2.30 0.73 20 ¡0.40 0.75
MBL <500 g/L versus 
MBL >500 g/L
0.90a
Fig. 2 Mean change from prior assessment to follow-up assessment of
¡18.3 (p = 0.0001). 95% CI: [¡27; ¡10]. 0 = no sickness, 100 = very
sick
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Fig. 3 Mean change from prior assessment to follow-up assessment of
7.3 (p = 0.072). 95% CI: [¡0.7; 15]. 0 = worst possible quality,
100 = best possible quality of life
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be involved. HSDI were useful to show better laryngeal
function after treatment.
One possible explanation of eVect is that the mucosa in
the upper airways in the dystonia syndrome is related to
neurological sensors in the mucosa, even if the dystonia is
universal. Another speculation may be that the voice and
the upper airway mucosa has a much more integrated func-
tion, not yet understood, for regulating the symptoms of
dystonia. Repairing the histamine-related function in itself
can have yet undeWned results [24, 25].
One other possible explanation is that the dopamine D1
receptor is involved in voicing in animal experiments and
ablation of D1 dopamine receptor—expressing cells, gener-
ates mice with seizures, dystonia, hyperactivity and
impaired oral behaviour are shown in an animal study with
advanced brain measures [26, 27]. A review of the neural
control of vocalisation in mammals includes pharmacologi-
cal activation of the neurotransmitter histamine stimulation
in synapses in the periaqueductal grey [28].
With the clinically relevant improvement of the symp-
tom status of dystonia of nearly 20% after 6–12 months,
future studies on the immune system related to the eVects of
fexofenadin tablets and budesonid inhaler locally in the
throat seem relevant to pursuit. With the traumas in the per-
sonal history of patients with the dystonia disorder even a
small change of the quality of life must be noted.
The high-speed images (HSDI) are interesting for the
documentation of neurological deviations of the larynx
because the true movement of the vocal cords and the
laryngeal vestibule are captured (Fig. 4).
Fig. 4 Segmentation curves. 
Segmentation curves for high-
speed Wlm calculations of open 
quotients in the front, center and 
rear parts of the vocal cords. 
Visual irregularities are 
illustrated due to a dystonia 
spasm—on movement curves 
of the vocal cords in front, center 
and rear, as well as area-, acous-
tical-, electroglottographical-, 
and kymographical curves1482 Eur Arch Otorhinolaryngol (2012) 269:1477–1482
123
ScientiWc treatment documentation of the dystonia syn-
drome has mostly been carried out in animals. Careful evi-
dence-based study designs are needed in the future as for
study baselines, populations and statistical power calcula-
tions in humans. A supplementary study of antibodies has
been suggested [29]. Central nucleus stimulation within the
brain is a new treatment. Certainly, aspects of the immune
system in the brain should be taken into account related to
voicing, on an earlier stage, before operations on dystonia
are considered [30]. Local immunological and eventual
genetic aspects of the upper airways must be focused upon.
In summary, the results of this study indicates that the
group of dystonia patients with low MBL (MBL <500 g/L)
responds to the treatment with local steroid inhaler of
budesonid and antihistamine fexofenadin as well as the
patients with normal levels of MBL. Other immune system-
related factors should systematically be analysed in the
future.
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